Abingworth
About Abingworth
Abingworth is a trans-atlantic bio-science investment firm that works with entrepreneurs to turn breakthrough science into breakthrough medicine. With over thirty years of experience, they have invested in over a hundred young companies and helped them navigate through various scenarios to build successful companies.
Recent News
Pharma Funding Roudup: Kardigan Announces $400 Million Initial IPO, cAMPfield Launches with $180 Million Series A
Addition Therapeutics Inks $100 Million Funding
Addition Therapeutics Shows Durable Gene‑Editing Proof‑of‑Concept at ASGCT
Solve Therapeutics Secures $120 Million
New Biotech cAMPfield Emerges with $180M to Reshape IBD Treatment
UK Tech Funding Roundup: This Week’s Deals From Quantum Motion to Lunar
Recent Deals
CAMPfield Therapeutics Raises $180M Series A to Advance Oral PDE4 Inhibitor for IBD
Solve Therapeutics Raises $120M in Oversubscribed Funding Round
Addition Therapeutics Secures $100M Funding to Advance Genomic Medicine
R1 Therapeutics Raises $77.5M Series A to Advance Kidney Disease Drug
Cytospire Raises $83M Series A to Develop Pan‑gamma Delta T‑cell Engagers